Biosergen AB (BIOSGN) AI Stock Analysis

• Market Cap: kr118.82M
• Dividend Yield: N/A
• Average Volume (3M): 102.68K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.27
• Revenue Growth: N/A
• EPS Growth: 65.16%
• Country: SE
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 234,823,210
• 10 Day Avg. Volume: 71,020
• 30 Day Avg. Volume: 102,680
• PEG Ratio: 0.08
• Price to Book (P/B): 2.64
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 34 Underperform
• Price Target: ―

Biosergen AB's overall stock score is low due to significant financial challenges, including persistent losses, no revenue growth, and negative cash flows. The technical indicators are weak, with the stock trading below key moving averages and a negative MACD. The valuation is also unattractive due to the negative P/E ratio and lack of dividends. These factors contribute to a cautious outlook for the stock.

Biosergen AB Business Overview & Revenue Model

Company Description

Biosergen AB (BIOSGN) is a biotechnology company focused on the research and development of novel antifungal therapies. The company operates in the healthcare sector, particularly within the pharmaceutical and biotechnology industries. Its core product pipeline includes innovative antifungal compounds aimed at addressing unmet needs in the treatment of fungal infections.

How the Company Makes Money

Biosergen AB generates revenue primarily through the development and commercialization of its antifungal drug candidates. The company engages in various stages of clinical trials to bring its products to market, potentially partnering with larger pharmaceutical firms for distribution and marketing. Additionally, Biosergen may secure funding through grants, collaborations, and licensing agreements with other organizations interested in its research and development efforts. These partnerships and agreements often provide upfront payments, milestone payments, and royalties on future sales, contributing to the company's earnings.

Biosergen AB Financial Statement Overview

Summary

Biosergen AB is facing significant financial challenges, with persistent losses, no revenue growth, and negative cash flows. The company's strong equity position and lack of debt are positive, but they are overshadowed by operational inefficiencies and inability to generate revenue. Without a clear path to profitability or revenue generation, the financial outlook remains weak.

Income Statement

Biosergen AB has consistently reported zero revenue for the past two years, indicating potential challenges in product commercialization or market entry. The company has high negative EBIT and net income, reflecting operational inefficiencies and significant losses. The lack of revenue growth and negative profit margins are major concerns, impacting the overall financial health of the company.

Balance Sheet

The balance sheet shows a high level of stockholders' equity relative to total assets, with an equity ratio of approximately 93% in 2024. The company has no debt, which is a positive aspect, but the significant negative net income affects the return on equity, leading to inefficiencies. Lack of revenue growth could pose risks to maintaining this equity position in the future.

Cash Flow

The company has a negative free cash flow, indicating a reliance on external financing to cover operating expenses. The operating cash flow is also negative, highlighting challenges in generating cash from operations. The cash flow situation could be concerning if the company cannot improve its cash generation ability or secure further financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	8.57M	4.43M
Gross Profit	0.00	0.00	-456.00K	-280.00K	-213.60K	-6.10M
EBITDA	-24.15M	-19.20M	228.00K	-39.99M	-34.32M	-6.72M
Net Income	-24.27M	-19.20M	-27.04M	-34.05M	-34.32M	-6.72M
Balance Sheet
Total Assets	37.93M	52.85M	7.20M	33.79M	29.49M	4.80M
Cash, Cash Equivalents and Short-Term Investments	33.27M	50.61M	1.88M	29.34M	21.66M	589.00K
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	5.35M	3.71M	5.08M	11.00M	9.25M	15.72M
Stockholders Equity	32.58M	48.21M	2.12M	22.79M	20.23M	-10.92M
Cash Flow
Free Cash Flow	-14.15M	-16.63M	-32.60M	-29.44M	-37.75M	-4.58M
Operating Cash Flow	-14.15M	-16.63M	-32.60M	-29.44M	-37.75M	-4.58M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	41.09M	65.36M	5.14M	37.12M	58.83M	0.00

Biosergen AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.50
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOSGN, the sentiment is Neutral. The current price of 0.5 is below the 20-day moving average (MA) of 0.50, above the 50-day MA of 0.49, and above the 200-day MA of 0.47, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.86 is Neutral, neither overbought nor oversold. The STOCH value of 54.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:BIOSGN.

Biosergen AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALZ	56 Neutral	€186.74M	―	-20.22%	―	-67.00%	23.63%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NXTCL	47 Neutral	kr104.71M	―	-89.24%	―	-15.28%	36.01%
NICA	41 Neutral	€103.82M	―	-180.76%	―	167.59%	48.11%
SPAGO	38 Underperform	kr57.97M	―	-90.43%	―	-16.01%	59.53%
BIOSGN	34 Underperform	kr118.82M	―	-101.53%	―	―	65.16%